Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 19.87% is 105% above its 5-year average of -421.34%, near the high end of its 5-year range (-17241.13%–990.93%).
100.34% above its 12-month average of -5821.56%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 50.00%.
NET PROFIT MARGIN
19.87%
NET PROFIT MARGIN AVG TTM
-5821.56%
NET PROFIT MARGIN AVG 3Y
-724.72%
NET PROFIT MARGIN AVG 5Y
-421.34%
NET PROFIT MARGIN AVG 10Y
-330.33%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+100.34%
CURRENT VS 3Y AVG
+102.74%
CURRENT VS 5Y AVG
+104.72%
CURRENT VS 10Y AVG
+106.02%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+7742.31%
vs the sector median at left
MeiraGTx Holdings plc
Market Cap
$987.63M
Net Profit Margin
19.87%
TTM Avg
-5821.56%
3Y Avg
-724.72%
5Y Avg
-421.34%
Market Cap
$987.62M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$988.73M
Net Profit Margin
-32.54%
TTM Avg
-35.87%
3Y Avg
-66.42%
5Y Avg
-187.72%
Market Cap
$997.02M
Net Profit Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$976.29M
Net Profit Margin
1.96%
TTM Avg
-6.61%
3Y Avg
-1.16%
5Y Avg
6.17%
Market Cap
$1.00B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$968.76M
Net Profit Margin
-727.04%
TTM Avg
-1969.28%
3Y Avg
-984.64%
5Y Avg
-984.64%
Market Cap
$1.01B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-57.69%
Market Cap
$1.02B
Net Profit Margin
-2.66%
TTM Avg
-7.26%
3Y Avg
-9.19%
5Y Avg
-9.19%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | $987.63M | 19.87% | -5821.56% | -724.72% | -421.34% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $987.62M | 0.00% | 0.00% | 0.00% | 0.00% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $988.73M | -32.54% | -35.87% | -66.42% | -187.72% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $997.02M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $976.29M | 1.96% | -6.61% | -1.16% | 6.17% |
| Vor Biopharma Inc. (VOR)vs › | $1.00B | 0.00% | 0.00% | 0.00% | 0.00% |
| Aktis Oncology, Inc. (AKTS)vs › | $968.76M | -727.04% | -1969.28% | -984.64% | -984.64% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | 0.00% | 0.00% | 0.00% | -57.69% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | -2.66% | -7.26% | -9.19% | -9.19% |
| Savara Inc. (SVRA)vs › | $953.94M | 0.00% | 0.00% | 0.00% | -3217.58% |
Operating Margin
-130.2%
Net Profit Margin
19.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 50.00% |
| 2026-03-31 | -15806.48% |
| 2025-12-31 | 20.02% |
| 2025-09-30 | -12320.24% |
| 2025-06-30 | -1051.07% |
| 2025-03-31 | -2075.86% |
| 2024-12-31 | -184.19% |
| 2024-09-30 | -360.49% |
| 2024-06-30 | -17241.13% |
| 2024-03-31 | -2932.86% |
| 2023-12-31 | 990.93% |
| 2023-09-30 | -868.06% |
| 2023-06-30 | -835.62% |
| 2023-03-31 | -910.74% |
| 2022-12-31 | 516.51% |
| 2022-09-30 | -774.17% |
| 2022-06-30 | -315.76% |
| 2022-03-31 | -551.13% |
| 2021-12-31 | -47.10% |
| 2021-09-30 | -373.47% |
| 2021-06-30 | -392.61% |
| 2021-03-31 | -513.97% |
| 2020-12-31 | -276.17% |
| 2020-09-30 | -126.32% |
| 2020-06-30 | -1027.41% |
| 2020-03-31 | -372.51% |
| 2019-12-31 | -78.95% |
| 2019-09-30 | -291.99% |
| 2019-06-30 | -1050.75% |
| 2019-03-31 | -2290.81% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
